Skip to main content
BIFIDO. Co. Ltd logo

BIFIDO. Co. Ltd — Investor Relations & Filings

Ticker · 238200 ISIN · KR7238200000 KO Manufacturing
Open in API
Filings indexed 220 across all filing types
Latest filing 2020-03-19 Proxy Solicitation & In…
Country KR South Korea
Listing KO 238200

About BIFIDO. Co. Ltd

https://bifido.com/

BIFIDO Co., Ltd. is a biotechnology company established in 1999 that specializes in the human microbiome. The company's core focus is the research and development of human-derived Bifidobacterium strains for use in functional foods, supplements, and personal care products. BIFIDO operates an integrated platform that covers the entire process from the selection of probiotic and pharmabiotic candidates to the manufacturing of finished goods, marketed under brands like BIFIDOLAB. Its research, supported by extensive scientific papers and patents, targets areas such as immune regulation, cognitive health, and the development of microbiome-based therapeutics for various health conditions.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고). It details specific corrections made to the financial statements (consolidated and separate) that were originally included in the notice. Since this is a formal regulatory filing submitted to the DART system (indicated by the DART reference and the structure of the correction table), and it is a correction to a proxy-related document (the notice of the meeting), it falls under the category of Proxy Solicitation & Information Statement (PSI) as it relates to the materials provided to shareholders for the meeting.
2020-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Bifido Co., Ltd. It contains the meeting agenda, details on voting rights, and management information, including financial statements (balance sheets, income statements, etc.) provided as reference materials for the upcoming Annual General Meeting. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on agenda items at the meeting.
2020-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Bifido) announcing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit is completed. It fits the definition of a general regulatory announcement regarding financial performance, which falls under the RNS (Regulatory Filings) category.
2020-02-27 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company Bifido. It outlines the date, location, and agenda items (such as approval of financial statements and director compensation) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation/notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2020-02-27 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal notification filed by Bifido regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the internal and external reasons for choosing this specific date. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2020-02-27 Korean
기타경영사항(특허권취득)(자율공시)(부티릴 프락토올리고당을 포함하는 프리바이오틱스 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by the company Bifido. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2020-02-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.